• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SRAX Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Events That Accelerate or Increase a Direct Financial Obligation, Unregistered Sales of Equity Securities, Financial Statements and Exhibits

    11/6/23 5:15:25 PM ET
    $SRAX
    Advertising
    Consumer Discretionary
    Get the next $SRAX alert in real time by email
    false 0001538217 0001538217 2023-11-06 2023-11-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

      Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported) November 6, 2023 (October 31, 2020)

     

    Commission File Number 001-37916

     

    SRAX, Inc.

    (Exact name of registrant as specified in its charter)

     

    Delaware   45-2925231

    (State or other jurisdiction

    of incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

         

    1014 S. Westlake Blvd., Suite 14-29

    Westlake Village, CA

      91361
    (Address of principal executive offices)   (Zip Code)

     

    Registrant’s telephone number, including area code (323) 205-6109

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Class A Common Stock, $0.001 par value   SRAX   N/A
    (Title of each class)   (Trading Symbol)   (Name of each exchange on which registered)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☐

     

    If an emerging growth company, indicate by checkmark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

     

    Item 1.01 Entry into a Material Definitive Agreement.

     

    On November 2, 2023, SRAX, Inc. (the “Company”) entered into definitive securities purchase agreements (the “Securities Purchase Agreement”) with certain accredited and institutional investors (the “Purchasers”) for the purchase and sale of an aggregate of: (i) $552,000 in principal amount of Original Issue Discount Convertible Debenture (the “Debentures”) for $460,000 (representing a 20% original issue discount) (“Purchase Price”) and (ii) warrants to purchase up to 3,680,000 shares of the Company’s Class A common stock (the “Warrants”) in a private placement (the “Offering”) exempt from registration under the Securities Act of 1933, as amended (the “Securities Act”), in reliance on the exemption provided by Rule 506(b) of Regulation D and Section 4(a)(2) of the Securities Act.

     

    The Debentures, which mature on November 3, 2024, pay 0%, no interest per annum commencing on November 3, 2023. In the event a Purchaser converts a portion of its Debenture into Common Stock, such amount will be deducted from the principle balance.

     

    The Debentures are convertible at the option of the holder into shares of our Class A common stock (“Common Stock”) at an initial conversion price of $0.25 per share, subject to adjustment in the event of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata distributions, and (iv) certain fundamental transactions, including but not limited to the sale of the Company, business combinations, and reorganizations (v) subsequent equity sales.

     

    Conversions are limited to the “Beneficial Ownership Limitation”, which shall be 4.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock issuable upon conversion of this Note held by the Holder. The Holder, upon not less than 61 days’ prior notice to the Company, may increase or decrease the Beneficial Ownership Limitation provisions of this Section 4(d), provided that the Beneficial Ownership Limitation in no event exceeds 9.99% of the number of shares of the Common Stock outstanding immediately after giving effect to the issuance of shares of Common Stock upon conversion of this Note held by the Holder and the Beneficial Ownership Limitation provisions of this Section 4(d) shall continue to apply

     

    Subject to our compliance with certain equity conditions, (as more fully set forth in the Debentures), upon ten (5) trading days’ notice to the Purchasers, the Company has the right to prepay the Debentures in cash at 120% of their outstanding principal, plus accrued interest for the first 90 days of the note and 135% thereafter.

     

    The Debentures also contain certain customary events of default provisions, including, but not limited to, default in payment of principal, changes in control of the Company. Upon the occurrence of any such event of default, the outstanding principal amount of the Debenture plus liquidated damages, interest and other amounts owing in respect thereof through the date of acceleration, shall become, at the Purchaser’s election, immediately due and payable in cash.

     

    The Warrants are initially exercisable at .25 per share and, are subject to cashless exercise after six months if the shares underlying the Warrants are not subject to an effective resale registration statement. The Warrants are also subject to adjustment in the event of (i) stock splits and dividends, (ii) subsequent rights offerings, (iii) pro-rata distributions, and (iv) certain fundamental transactions, including but not limited to the sale of the Company, business combinations, and reorganizations. (v) subsequent equity sales.

     

    Pursuant to the terms of the Debentures and Warrants, a Purchaser will not have the right to convert any portion of the Warrants if the holder (together with its affiliates) would beneficially own in excess of 4.99% or 9.99% (at the Purchaser’s option) of the number of shares of Common Stock outstanding immediately after giving effect to such conversion or exercise, as such percentage ownership is determined in accordance with the terms of the Debentures and the Warrants; provided that at the election of a holder and notice to us such percentage ownership limitation may be increased to 9.99%; provided that any increase will not be effective until the 61st day after such notice is delivered from the holder to the Company.

     

    The Offering closed on November 3, 2023.

     

     

     

     

    The securities offered have not been registered under the Securities Act, and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements. This current report shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state.

     

    The foregoing summaries of each of the Securities Purchase Agreement, the Registration Rights Agreement, the Security Agreement, the Debentures, and the Warrants are qualified in their entirety by reference to the full text of each such document, a copy of the form of each is attached hereto as Exhibits 10.01, 10.02, 10.03, 4.01, and 4.02, respectively, and each of which is incorporated herein in its entirety by reference.

     

    Pursuant to the rights entered into with our senior secured lender as filled in for 8K on September 14, 2023, the lender has the rights to convert any cash payments due to them into a subsequent equity offering. The lender has opted to convert $454,202 of amounts owed into the above referenced note at the same terms and conditions. The lender shall be issued 3,633,616 warrants per the agreements listed above.

     

    Item 2.03 Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.

     

    The information set forth above in Item 1.01 of this current report on Form 8-K is incorporated herein by reference in its entirety.

     

    Item 2.04 Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement.

     

    The information set forth above in Item 1.01 of this current report on Form 8-K is incorporated herein by reference in its entirety.

     

    Item 3.02 Unregistered Sale of Equity Securities.

     

    The information set forth above in Item 1.01 of this current report on Form 8-K is incorporated herein by reference in its entirety.

     

    Item 9.01 Financial Statements and Exhibits.

     

    Exhibit Number   Description
         
    4.01   Form of Original Issue Discount Convertible Debenture
    4.02   Form of Common Stock Purchase Warrant
    10.01   Form of Securities Purchase Agreement
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Date: November 6, 2023   SRAX, Inc.
         
        /s/ Christopher Miglino
      By:  Christopher Miglino
        Chief Executive Officer

     

     

    Get the next $SRAX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SRAX

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $SRAX
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Miglino Christopher bought $750 worth of SRAX Common Stock (15,000 units at $0.05), increasing direct ownership by 2% to 902,575 units (SEC Form 4)

    4 - SRAX, Inc. (0001538217) (Issuer)

    12/28/23 5:25:44 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    $SRAX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    SRAX Signs Agreement to Merge with DNA Holdings

    Westlake Village, CA, May 08, 2024 (GLOBE NEWSWIRE) -- SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, announced today it has entered into a definitive merger agreement with DNA Holdings Venture Inc. pursuant to which the shareholders of DNA will become the majority owners of SRAX's outstanding common stock as more fully described below upon the closing of the merger. DNA has been a long term investor in SRAX and currently owns approximately 35% of the company.  DNA is  a Web3 investment company which provides both advisory services and invests in Web3 infrastructure. The company was foun

    5/8/24 8:00:00 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SRAX SELECTS XDEFI AS WEB3 WALLET PARTNER, ENABLING SECURE ACCESS TO DIGITAL ASSETS FOR ACTIVE EQUITY INVESTORS

    Los Angeles, March 05, 2024 (GLOBE NEWSWIRE) -- Los Angeles, [5 March 2024] - SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, today announced it has selected XDEFI as its Web3 wallet partner. XDEFI is a pioneering multichain cryptocurrency wallet. The partnership will enable SRAX's network of active equity investors to access decentralized applications and assets spanning 200+ blockchains, seamlessly and securely. In addition, SRAX clients who download the wallet will be eligible for airdrops in $XDEFI tokens and many future token airdrops.  In 2023, over $5 billion was given away through

    3/5/24 8:30:00 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SRAX SHAREHOLDER LETTER

    Westlake Village, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, As I write to you today, I do so with a sense of deep reflection on the year that has passed. It's been a period that tested our resilience. I want to express my sincere regret for the concerns and frustrations you may have experienced as a result of our stock price. Addressing Our Challenges Head-On Our delisting from the NASDAQ market was a moment for serious introspection. Looking back, there were areas where we should have been more proactive, especially as it relates to our accounting team's leadership and the complexities of the accounting for our business.  Bringing in new experts was a turning point for th

    12/18/23 7:00:00 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    $SRAX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Dawson James initiated coverage on SRAX with a new price target

    Dawson James initiated coverage of SRAX with a rating of Buy and set a new price target of $10.00

    4/19/21 9:31:00 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    B. Riley reiterated coverage on SRAX with a new price target

    B. Riley reiterated coverage of SRAX with a rating of Buy and set a new price target of $7.50 from $4.50 previously

    2/12/21 8:22:29 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    Ladenburg Thalmann initiated coverage on SRAX with a new price target

    Ladenburg Thalmann initiated coverage of SRAX with a rating of Buy and set a new price target of $7.00

    2/8/21 7:58:16 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    $SRAX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Miglino Christopher bought $750 worth of SRAX Common Stock (15,000 units at $0.05), increasing direct ownership by 2% to 902,575 units (SEC Form 4)

    4 - SRAX, Inc. (0001538217) (Issuer)

    12/28/23 5:25:44 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SEC Form 4 filed by Urban Alan Louis

    4 - SRAX, Inc. (0001538217) (Issuer)

    3/22/23 2:57:48 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SEC Form 3 filed by new insider Urban Alan Louis

    3 - SRAX, Inc. (0001538217) (Issuer)

    3/22/23 2:56:42 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    $SRAX
    SEC Filings

    View All

    SEC Form 10-Q filed by SRAX Inc.

    10-Q - SRAX, Inc. (0001538217) (Filer)

    4/30/25 6:18:31 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SEC Form 10-Q filed by SRAX Inc.

    10-Q - SRAX, Inc. (0001538217) (Filer)

    3/7/25 6:03:29 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SEC Form 10-K filed by SRAX Inc.

    10-K - SRAX, Inc. (0001538217) (Filer)

    9/20/24 5:29:24 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    $SRAX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    March 22, 2024 - FDA Roundup: March 22, 2024

    For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

    3/22/24 5:02:42 PM ET
    $SNAP
    $SRAX
    Computer Software: Programming Data Processing
    Technology
    Advertising
    Consumer Discretionary

    November 9, 2023 - FDA Approves First Treatment for Patients with Rare Inherited Blood Clotting Disorder

    For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

    11/9/23 2:30:20 PM ET
    $SRAX
    $SNAP
    Advertising
    Consumer Discretionary
    Computer Software: Programming Data Processing
    Technology

    $SRAX
    Leadership Updates

    Live Leadership Updates

    View All

    June 7, 2024 - FDA Roundup: June 7, 2024

    For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

    6/7/24 3:46:22 PM ET
    $GERN
    $SRAX
    $SNAP
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Advertising
    Consumer Discretionary

    SRAX Announces Appointment of New CFO

    Los Angeles, California--(Newsfile Corp. - March 20, 2023) - SRAX, Inc. (NASDAQ:SRAX), a leading financial technology company, has announced the appointment of Alan Urban as the CFO of SRAX. Mr. Urban has over 30 years of experience in corporate finance and accounting. He has previously served in numerous senior management positions, most notably as Chief Financial Officer for ten years at Research Solutions, a provider of SaaS solutions for life science organizations. Mr. Urban also serves on the Board of Directors of GT Biopharma."We are excited to have Alan step into this very important role at SRAX. We believe his 30 years of expertise will be instrumental in getting our accounting t

    3/20/23 9:00:00 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    ICOA Inc. Appoints SRAX to Enhance Investor Communications

    LAS VEGAS, NEVADA , April 14, 2022 (GLOBE NEWSWIRE) -- Publicly traded Nevada blockchain, decentralized finance (DeFi), and cryptocurrency-focused investment company ICOA Inc. (OTC:ICOA) announced this week that they have entered a $500,000 deal with SRAX (NASDAQ:SRAX) to maximize and accelerate its communications for interested investors, shareholders, and supporters. Through SRAX, a publicly traded company offering premier operating system tools for publicly traded companies, ICOA will have the ability to further reach its community through sophisticated solutions to assist it in maintaining, communicating, and expanding its shareholder base. With Sequire, a product of SRAX, IC

    4/14/22 9:42:39 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    $SRAX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

    SC 13G/A - SRAX, Inc. (0001538217) (Subject)

    2/14/24 2:56:29 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

    SC 13G/A - SRAX, Inc. (0001538217) (Subject)

    2/13/24 7:42:04 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    SEC Form SC 13G/A filed by SRAX Inc. (Amendment)

    SC 13G/A - SRAX, Inc. (0001538217) (Subject)

    2/14/23 3:07:08 PM ET
    $SRAX
    Advertising
    Consumer Discretionary

    $SRAX
    Financials

    Live finance-specific insights

    View All

    SRAX Reassures Investors of Business Health Amid Delisting Notice

    Los Angeles, California--(Newsfile Corp. - March 9, 2023) - SRAX, Inc. (NASDAQ:SRAX), a financial technology company that provides data and insights to publicly traded companies through its SaaS platform Sequire, would like to reassure its investors that the company's core business remains strong despite the recent delisting notice from NASDAQ. The delisting was caused by a late filing, and the company is actively working to regain compliance as soon as possible.We are pleased to report that SRAX has added over 25 new customers in the first quarter of 2023, indicating the strength of our business and the value we provide to our clients. We remain confident that this momentum will continue, a

    3/9/23 9:00:00 AM ET
    $SRAX
    Advertising
    Consumer Discretionary

    Freedom Holding Acquires LD Micro From SRAX, Inc.

    Purchase brings pre-eminent small-cap platform to the Freedom family Freedom U.S. Markets, LLC, a wholly-owned subsidiary of Freedom Holding Corp. (NASDAQ:FRHC), announced today that it has completed the acquisition of LD Micro from SRAX, Inc. (NASDAQ:SRAX). The total consideration of $8.3 million includes $4 million in cash and FRHC common stock valued at $4.3 million. LD Micro offers two premier small-cap conferences annually, the Invitational: June 6-8 (Los Angeles) and the Main Event: October 3-5 (Los Angeles), which hosts over 200 companies and 1,000 investors. For the past 15 years, the LD Micro conferences have showcased the next big names in the small-cap world to investors and i

    3/6/23 8:00:00 AM ET
    $FRHC
    $SRAX
    Investment Bankers/Brokers/Service
    Finance
    Advertising
    Consumer Discretionary

    SRAX Acquires DNA Holdings Assets

    Los Angeles, California--(Newsfile Corp. - February 6, 2023) - SRAX, Inc. (NASDAQ:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has acquired the assets of DNA Holdings, LLC.DNA specializes in helping private technology companies with positioning, marketing, and strategy. The emphasis on private companies provides the expertise for SRAX to accelerate the entrance into the cap table management for private companies. The private cap table management market is anticipated to grow to over $1 Billion by 2030. This market is a natural extension of SRAX's current Sequire Platform that helps public companies m

    2/6/23 8:30:00 AM ET
    $SRAX
    Advertising
    Consumer Discretionary